BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 24672017)

  • 1. Mechanisms of dopamine D1 receptor-mediated ERK1/2 activation in the parkinsonian striatum and their modulation by metabotropic glutamate receptor type 5.
    Fieblinger T; Sebastianutto I; Alcacer C; Bimpisidis Z; Maslava N; Sandberg S; Engblom D; Cenci MA
    J Neurosci; 2014 Mar; 34(13):4728-40. PubMed ID: 24672017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of metabotropic glutamate receptor 5 attenuates axonal degeneration in 6-hydroxydopamine-induced model of Parkinson's disease.
    Zhang JN; Huang YL; Yang HM; Wang Y; Gu L; Zhang H
    Mol Cell Neurosci; 2021 Jan; 110():103572. PubMed ID: 33248235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine D1 receptor modulation of glutamate receptor messenger RNA levels in the neocortex and neostriatum of unilaterally 6-hydroxydopamine-lesioned rats.
    Rodríguez-Puertas R; Herrera-Marschitz M; Koistinaho J; Hökfelt T
    Neuroscience; 1999 Mar; 89(3):781-97. PubMed ID: 10199613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prior D1 dopamine receptor stimulation is required to prime D2-mediated striatal Fos expression in 6-hydroxydopamine-lesioned rats.
    Pollack AE; Yates TM
    Neuroscience; 1999; 94(2):505-14. PubMed ID: 10579212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
    St-Hilaire M; Landry E; Lévesque D; Rouillard C
    Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat.
    Dupre KB; Eskow KL; Barnum CJ; Bishop C
    Neuropharmacology; 2008 Dec; 55(8):1321-8. PubMed ID: 18824001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reciprocal cross-sensitization of D1 and D3 receptors following pharmacological stimulation in the hemiparkinsonian rat.
    Lanza K; Chemakin K; Lefkowitz S; Saito C; Chambers N; Bishop C
    Psychopharmacology (Berl); 2020 Jan; 237(1):155-165. PubMed ID: 31435690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.
    Fiorentini C; Savoia P; Savoldi D; Barbon A; Missale C
    Neurobiol Dis; 2013 Jun; 54():339-48. PubMed ID: 23328768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats.
    Yamamoto N; Soghomonian JJ
    Neuroscience; 2009 Nov; 163(4):1171-80. PubMed ID: 19660528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic Knockdown of mGluR5 in Striatal D1R-Containing Neurons Attenuates L-DOPA-Induced Dyskinesia in Aphakia Mice.
    García-Montes JR; Solís O; Enríquez-Traba J; Ruiz-DeDiego I; Drucker-Colín R; Moratalla R
    Mol Neurobiol; 2019 Jun; 56(6):4037-4050. PubMed ID: 30259400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum.
    Doucet JP; Nakabeppu Y; Bedard PJ; Hope BT; Nestler EJ; Jasmin BJ; Chen JS; Iadarola MJ; St-Jean M; Wigle N; Blanchet P; Grondin R; Robertson GS
    Eur J Neurosci; 1996 Feb; 8(2):365-81. PubMed ID: 8714707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential enhancement of ERK, PKA and Ca
    Mariani LL; Longueville S; Girault JA; Hervé D; Gervasi N
    Neurobiol Dis; 2019 Oct; 130():104506. PubMed ID: 31220556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. D1-mGlu5 heteromers mediate noncanonical dopamine signaling in Parkinson's disease.
    Sebastianutto I; Goyet E; Andreoli L; Font-Ingles J; Moreno-Delgado D; Bouquier N; Jahannault-Talignani C; Moutin E; Di Menna L; Maslava N; Pin JP; Fagni L; Nicoletti F; Ango F; Cenci MA; Perroy J
    J Clin Invest; 2020 Mar; 130(3):1168-1184. PubMed ID: 32039920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
    Suárez LM; Solís O; Caramés JM; Taravini IR; Solís JM; Murer MG; Moratalla R
    Biol Psychiatry; 2014 May; 75(9):711-22. PubMed ID: 23769604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic interaction between an adenosine antagonist and a D1 dopamine agonist on rotational behavior and striatal c-Fos induction in 6-hydroxydopamine-lesioned rats.
    Pollack AE; Fink JS
    Brain Res; 1996 Dec; 743(1-2):124-30. PubMed ID: 9017239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine receptor cooperativity synergistically drives dyskinesia, motor behavior, and striatal GABA neurotransmission in hemiparkinsonian rats.
    Kiessling CY; Lanza K; Feinberg E; Bishop C
    Neuropharmacology; 2020 Sep; 174():108138. PubMed ID: 32492451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons.
    Frau L; Morelli M; Simola N
    Exp Neurol; 2013 Sep; 247():663-72. PubMed ID: 23499830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.
    Iderberg H; Rylander D; Bimpisidis Z; Cenci MA
    Exp Neurol; 2013 Dec; 250():116-24. PubMed ID: 24029003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
    Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M
    Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BDNF Overexpression Increases Striatal D3 Receptor Level at Striatal Neurons and Exacerbates D1-Receptor Agonist-Induced Dyskinesia.
    Scheggi S; Rossi F; Corsi S; Fanni S; Tronci E; Ludovica C; Vargiu R; Gambarana C; Muñoz A; Stancampiano R; Björklund A; Carta M
    J Parkinsons Dis; 2020; 10(4):1503-1514. PubMed ID: 32651332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.